Monday, December 19, 2011

ChromaDex Announces Completion of Patient Enrollment for the First Human Clinical Study of its Proprietary pTeroPure

ChromaDex Announces Completion of Patient Enrollment for the First Human Clinical Study of its Proprietary pTeroPurePalm Beach, FL 12/19/11 (StreetBeat) -- ChromaDex Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries today announced the successful completion of enrollment in the first human clinical study of its proprietary pTeroPure.

The purpose of the randomized, double-blind placebo-controlled study is to evaluate whether pTeroPure will lower cholesterol and blood pressure, as well as improve markers for oxidative stress in patients with dyslipidemia-meeting inclusion criteria. Investigators are also evaluating the safety of pTeroPure in these patients.

pTeroPure is ChromaDex's proprietary brand of its patent-pending pterostilbene, a central ingredient in its recently launched BluScience™ line of dietary supplements, now available at GNC.

Pterostilbene is one of several stilbenes found in blueberries and other berries that have demonstrated pre-clinical benefits in a number of health factors including improved levels of cholesterol, blood pressure and oxidative stress.

ChromaDex holds exclusive worldwide rights to patents pending for pterostilbene for these and other health benefits based on technology licensed from the University of Mississippi , as well as through additional intellectual property developed by the company or in conjunction with leading research institutions.

William Spengler , President of ChromaDex, said, "Now that trial enrollment is successfully completed, we anticipate release of the trial data in Q2 2012. This first human clinical study of pTeroPure will provide an important independent clinical assessment of what we believe is an enormous opportunity with this product. We anticipate that additional clinical studies involving pTeroPure and other compounds in our pipeline will be initiated in the coming months."

pTeroPure was recently named the 2010 North American Most Promising Ingredient of the Year by the prestigious independent research company Frost & Sullivan. Capitalizing on the diverse potential applications of the product, ChromaDex is also developing pTeroPure for the skincare and pharmaceutical markets, among others.

StreetBeat Disclaimer

Distributed by Viestly

No comments:

Post a Comment